Overview

Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage

Status:
Completed
Trial end date:
2003-03-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the safety and preliminary efficacy of activated recombinant human factor VII (NovoSeven®) for preventing early hematoma growth in acute Intracerebral Hemorrhage (ICH).
Phase:
Phase 2
Details
Lead Sponsor:
Novo Nordisk A/S